Millennium Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Millennium Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-130,900	Closed	-$2.73M	–	6011
2023 Q3	$2.73M	Buy	+130,900	New	+$3.56M	﹤0.01%	3271
2018 Q3	–	Sell	-100,000	Closed	-$1.53M	–	3847
2018 Q2	$1.53M	Buy	+100,000	New	+$1.78M	﹤0.01%	2582
2017 Q1	–	Sell	-25,000	Closed	-$721K	–	3442
2016 Q4	$721K	Sell	25,000 -25,000	-50%	-$661K	﹤0.01%	2435
2016 Q3	$1.59M	Buy	+50,000	New	+$1.7M	﹤0.01%	2051
2016 Q2	–	Sell	-225,000	Closed	-$6.29M	–	3130
2016 Q1	$6.29M	Buy	+225,000	New	+$4.91M	0.02%	1117
2013 Q4	–	Sell	-14,600	Closed	-$401K	–	3411
2013 Q3	$401K	Sell	14,600 -105,700	-88%	-$2.21M	﹤0.01%	2692
2013 Q2	$2.18M	Buy	+120,300	New	+$1.66M	0.01%	1537

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management's ACAD Position: Q1 2026 in Review

Millennium Management increased its Acadia Pharmaceuticals (ACAD) stake by 27% in Q1 2026, buying an estimated $3.63M and bringing the position to 705,461 shares worth $15.7M. The position accounts for 0.01% of the portfolio, ranked #1750.

Millennium Management first reported a position in ACAD in Q2 2013 and has held it in 50 quarters since. The position peaked at $55.5M in Q4 2016. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Millennium Management held 705,461 shares of Acadia Pharmaceuticals worth $15.7M as of Q1 2026.
Millennium Management bought 151,787 Acadia Pharmaceuticals shares in Q1 2026, an estimated $3.63M.
Acadia Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1750 holding.
Millennium Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
Millennium Management's Acadia Pharmaceuticals position peaked at $55.5M in Q4 2016.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.